Patients are at the center of everything we do at GlycoMimetics. Through collaboration with our clinical partners, we are conducting clinical studies that explore the use of product candidates developed by our scientists in multiple oncology and other indications. Our central goal is to obtain the data required for review and approval by regulatory authorities, such as the U.S. Food and Drug Administration.
- Uproleselan (GMI-1271): This ongoing pivotal Phase 3 trial (NCT03616470) plans to enroll 380 patients ages 18 to 75 with relapsed/refractory acute myeloid leukemia who are considered to be medically eligible to receive intensive chemotherapy.
- Uproleselan (GMI-1271) is being evaluated by a consortium of the National Cancer Institute as a potential new treatment for newly diagnosed AML patients fit for chemotherapy. This is an ongoing effort with multiple sites across the U.S. participating.
- GMI-1359, a dual antagonist of E-selectin and CXCR4, is being evaluated in an ongoing proof-of-concept study at Duke University. Interim results will be reported at the AACR meeting in April, 2021.
Other Clinical Programs:
- Rivipansel: GlycoMimetics discontinued development of rivipansel for the treatment of vaso-occlusive crisis in sickle cell disease in early 2021, and instead, is preparing to initiate clinical development on a more potent molecule, GMI-1687, for potential subcutaneous administration in the outpatient setting. The company believes that the post hoc analyses of the rivipansel Phase 3 data sets confirmed the importance of E-selectin as a target and the necessity of treating early in VOC. To learn more about this program, please visit our Sickle Cell Disease program page.
- To learn more about other clinical trials involving our product candidates, please visit ClinicalTrials.gov: a publicly and privately supported registry of clinical studies involving human participants conducted around the world. To find information on trials run by GlycoMimetics, our development partners, or by independent investigators, use the “Search for Studies” function and enter the product candidate’s name (e.g., uproleselan).